Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL by Eduardo.

Slides:

Advertisements

Similar presentations

Pharmacogenetics of outcome in children with acute lymphoblastic leukemia by Jose Claudio C. Rocha, Cheng Cheng, Wei Liu, Shinji Kishi, Soma Das, Edwin.

Advertisements

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.

Novel Assay for Ex Vivo Evaluation of Antiproliferative Effect of Hypomethylating Agents 5-Azacytidine and Decitabine in AML Patient Samples by Pilar Hernandez,

Single-Unit Umbilical Cord Blood Transplantation from Unrelated Donors in Adult Patients with Chronic Myelogenous Leukemia Jaime Sanz, Pau Montesinos,

High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma by Jacopo Mariotti, Anna Guidetti, Michele Magni,

Single-Unit Umbilical Cord Blood Transplantation from Unrelated Donors in Adult Patients with Chronic Myelogenous Leukemia Jaime Sanz, Pau Montesinos,

Patterns of relapse and outcome of elderly multiple myeloma patients treated as front- line therapy with novel agents combinations Aurelio Lopez, Maria-Victoria.

Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation:

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of.

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Impact on Outcomes of Human Leukocyte Antigen Matching by Allele-Level Typing in Adults with Acute Myeloid Leukemia Undergoing Umbilical Cord Blood Transplantation

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Association of Human Development Index with rates and outcomes of hematopoietic stem cell transplantation for patients with acute leukemia by Sebastian.

Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.

Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia by Alida Dominietto, Sarah Pozzi, Maurizio Miglino, Flavio Albarracin,

Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia

Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous.

Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura by Evaren E. Page, Johanna A. Kremer.

Acute promyelocytic leukemia, microgranular variant

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first.

How we choose factor VIII to treat hemophilia

Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias by David Gómez-Almaguer, Manuel Solano-Genesta,

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health.

Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results by Lionel Adès, Miguel A. Sanz,

Unrelated Transplantation for Poor-Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Outcome Analysis and Study of the Impact of Hematopoietic Graft.

Imatinib (IM) Plus Thalidomide (Thali), A Effective Combination For The Treatment Of Chronic Myeloid Leukemia (CML) Philadelphia ChromosomePositive (Ph.

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia by Davide Rossi, Silvia Rasi, Valeria.

The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score by Ollivier Legrand, Jean-Yves Perrot, Marion Baudard, Annie.

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis Armin Rashidi,

Complete remission through blast cell differentiation inPLZF/RARα-positive acute promyelocytic leukemia: in vitro and in vivo studies by Maria C. Petti,

by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T

Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital by Jeffrey E. Rubnitz, Mihaela Onciu, Stanley Pounds,

Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory.

Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age Years with Acute Myelogenous Leukemia in First.

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non- Hodgkin Lymphoma: Importance of Histology for Outcome Philippe Armand,

Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia by Floriana Manodoro, Jacek Marzec, Tracy.

Jacob M. Rowe Biology of Blood and Marrow Transplantation

Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission Jennifer L. Holter.

Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation Philippe Armand, Haesook T. Kim, Daniel.

A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms by Carolina Martínez-Laperche, Elena.

David Gómez-Almaguer, Guillermo J

Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation:

Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia by Jaime Sanz, Mi Kwon, Guiomar Bautista, Miguel.

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission by Sumithira Vasu, Jessica.

The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory.

Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation Merav Bar, Weigang Tong, Megan Othus,

Haplo-Cord Transplantation Using CD34+ Cells from a Third-Party Donor to Speed Engraftment in High-Risk Patients with Hematologic Disorders Mi Kwon,

Feasibility of minimal residual disease studies by multiparametric flow cytometry for acute myeloid leukemia in a developing country by Lorena Lobo de.

Effect of CD8+ Cell Content on Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies Federico Moscardó, Jaime Sanz, Francisco.

Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study by Marius Flasinski, Kira Scheibke, Martin Zimmermann,

Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study by Salyka Sengsayadeth, Katie.

Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia by Rosemary E. Gale,

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia by Benjamin L. Lampson, Haesook T. Kim, Matthew.

Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia by Sebastian.

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia by Robin Foà, Antonella Vitale,

The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia by Amy K. Keating, Jurgen Langenhorst, John.

How I treat T-cell acute lymphoblastic leukemia in adults

Balancing bleeding in brain metastases

Presentation transcript:

Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL by Eduardo M. Rego, Haesook T. Kim, Guillermo J. Ruiz-Argüelles, Maria Soledad Undurraga, Maria del Rosario Uriarte, Rafael H. Jacomo, Homero Gutiérrez-Aguirre, Raul A. M. Melo, Rosane Bittencourt, Ricardo Pasquini, Katia Pagnano, Evandro M. Fagundes, Maria de Lourdes Chauffaille, Carlos S. Chiattone, Lem Martinez, Luis A. Meillón, David Gómez-Almaguer, Hau C. Kwaan, Javier Garcés-Eisele, Robert Gallagher, Charlotte M. Niemeyer, Stanley L. Schrier, Martin Tallman, David Grimwade, Arnold Ganser, Nancy Berliner, Raul C. Ribeiro, Francesco Lo-Coco, Bob Löwenberg, and Miguel A. Sanz Blood Volume 121(11):1935-1943 March 14, 2013 ©2013 by American Society of Hematology

Organization of the IC-APL network for the diagnosis and treatment of a given case of APL. Actions taken at the local centers are indicated in red and those taken at the national reference laboratories are indicated in blue. Organization of the IC-APL network for the diagnosis and treatment of a given case of APL. Actions taken at the local centers are indicated in red and those taken at the national reference laboratories are indicated in blue. (A) The interaction with the panel of international experts and the educational activities are shown in yellow. (B) Geographical distribution of the IC-APL institutions. Eduardo M. Rego et al. Blood 2013;121:1935-1943 ©2013 by American Society of Hematology

(A) OS and DSF and (B) cumulative incidence of relapse and cumulative incidence of nonrelapse mortality rates among patients with acute promyelocytic leukemia treated in the IC-APL study. (A) OS and DSF and (B) cumulative incidence of relapse and cumulative incidence of nonrelapse mortality rates among patients with acute promyelocytic leukemia treated in the IC-APL study. Eduardo M. Rego et al. Blood 2013;121:1935-1943 ©2013 by American Society of Hematology